Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL231312 | 0.98 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3KCNH2GABRA1 | |
| SCHEMBL20606457 | 0.87 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL20605786 | 0.87 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1968845 | 0.87 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL190820 | 0.85 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL26599567 | 0.84 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3KCNH2GABRA1 | |
| SCHEMBL14295197 | 0.83 | — | — | |
| SCHEMBL2744776 | 0.82 | CHRM2 (0.36) | SLC6A2SLC6A4SLC6A3KCNH2GABRA1 | |
| Tert-Butyl Formate SCHEMBL27812019 | 0.82 | TDP1 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2GABRA1 | |
| Hydrochloric Acid SCHEMBL4566681 | 0.80 | CYP4F2 (0.35) | LMNACYP4F2CYP4A11KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4412617-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2009024502-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | SLC6A2 4401/4885SLC6A4 4015/4885SLC6A3 4402/4885 |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | SLC6A2 4496/4885SLC6A4 3885/4885SLC6A3 4567/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | SLC6A2 1231/4885SLC6A4 1369/4885SLC6A3 1659/4885 |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | SLC6A2 861/4885SLC6A4 440/4885SLC6A3 347/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | SLC6A2 4814/4885SLC6A4 4658/4885SLC6A3 4598/4885 |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRD1, OPRK1 | SLC6A2 224/4885SLC6A4 188/4885SLC6A3 8/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | SLC6A2 3408/4885SLC6A4 2558/4885SLC6A3 1894/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | SLC6A2 4214/4885SLC6A4 4267/4885SLC6A3 3536/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | SLC6A2 3465/4885SLC6A4 4348/4885SLC6A3 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.